Prevalence and acceptance of methadone recommendations in hospice and palliative care by Kulkarni, Aishwarya
Duquesne University 
Duquesne Scholarship Collection 
Graduate Student Research Symposium 
2020-04-21 
Prevalence and acceptance of methadone recommendations in 
hospice and palliative care 
Aishwarya Kulkarni 
Follow this and additional works at: https://dsc.duq.edu/gsrs 
 Part of the Medicine and Health Sciences Commons 
Prevalence and acceptance of methadone recommendations in hospice and palliative care. (2020). 
Retrieved from https://dsc.duq.edu/gsrs/2020/proceedings/12 
This Poster is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted 
for inclusion in Graduate Student Research Symposium by an authorized administrator of Duquesne Scholarship 
Collection. 
Poster
BACKGROUND
OBJECTIVES
METHODS
RESULTS/TABLES
DISCUSSION
▪ Clinical pharmacists play an important role in the care of patients 
in hospice/palliative care, particularly for the treatment of pain
▪ One of the core responsibilities of a clinical pharmacist is 
recommending and optimizing individualized medication regimens 
▪ Methadone, a long-active opioid, is particularly useful for pain 
control in many patients in hospice/palliative care, but may be 
underutilized
PREVALENCE AND ACCEPTANCE OF METHADONE RECOMMENDATIONS IN HOSPICE 
AND PALLIATIVE CARE PATIENTS 
Kulkarni A1, Hawkins M 1, Kamal KM 1, Giannetti V 1, Mihalyo M 1,2, Covvey JR 1
1 Duquesne University School of Pharmacy, Pittsburgh, PA, USA
2 DeltaCareRx, Pittsburgh, PA, USA
▪ The objective of the study was to evaluate the prevalence of 
pharmacist recommendations and subsequent physician 
acceptance for the use of methadone for pain in newly admitted 
hospice/palliative care patients
▪ The study was conducted from October-December 2019 in coordination with a locally-
based pharmacy services organization which works with hospice/palliative care providers 
▪ A selected group of pharmacists at the organization identified new hospice/palliative care 
admissions as part of their usual clinical care process
▪ The first phase of data collected included patient demographics, type of pain, medication 
history, pain intensity and palliative prognosis score (range: 1-100) at the time of 
admission; furthermore, it identified whether a recommendation for methadone was made 
by the pharmacist based on individual indications/contraindications. 
▪ Patients who had recommendations for methadone rendered were followed up with a 
second phase of data collection by a member of the research team
▪ Further data collected included whether the provided recommendation was accepted or 
not, as well as additional patient information including allergies, comorbidities, 
hepatic/renal function, nutritional status pain medication history, current pain intensity 
and palliative prognosis score. 
▪ This research is currently a work-in-progress
▪ Data was analyzed for 158/159 patients based on adult hospice patient inclusion criteria of the study 
▪ The demographic and clinical characteristics of the patients collected through the tool aided the 
pharmacists in making a clinical judgement of providing methadone recommendation or not
▪ The mean sample age of the sample was 79.6 years (SD: 13.8 years) (Table 1)
▪ The mean palliative prognosis score was relatively stable between admission and follow-up (37.2 ±
12.2 vs 37.4 ± 12.1) (Table 1)
▪ Majority type of pain among the patients was nociceptive pain (62; 39.2), missing data on type of 
pain can limit the decision of providing methadone recommendation (Table 2)
▪ Higher utilization of home hospice compared to other hospice types (121; 76.6%) aligns with the 
published literature of this setting (Table 3)
▪ As per the traditional use, the sample population has higher opioids utilization for pain management 
compared to other medication categories (153; 96.8) (Table 4)
▪ Based on the pharmacists’ clinical judgments, 37 (23.4%) methadone recommendations were 
provided; out of which 8 (21.6 %) were accepted by the physicians within the follow-up period
▪ Out of the 8 accepted recommendation, 3 (37.5%) were implemented by the physicians themselves 
▪ The most common recommendation was for maintenance treatment (26; 16.5%) (Table 5)
▪ Majority of the patients were diagnosed with cardiovascular diseases as a comorbidity (116; 73.4%); 
it aligns with the data regarding common contraindication of prescribing methadone being QTc 
prolongation (38; 24.0%)  
▪ The common categories of allergies were antibiotics (46; 23.6%) and opioids (31; 15.6%); opioid 
allergic subpopulation was administered with alternative opioids for pain management 
▪ Clinical outcomes of methadone recommendation accepted patients cannot be extrapolated due to 
missing data in the follow-up period 
Table 1. Demographics 
n Mean (SD)
Height (m) 126 1.6 (0.1)
Weight (kg) 133 65.7 (15.1)
BMI (kg per m
2
) 125 23.8 (5.0)
Age (years) 156 79.6 (13.8)
Palliative prognosis score at admission 150 37.2 (12.1)
Palliative prognosis score at follow-up 146 37.4 (12.0)
Days from date of admission 135 21.2 (24.4)
Table 5. Types of methadone recommendations 
n (%)
Switch to maintenance treatment 26 (16.5)
Addition as adjunctive/adjuvant 7 (4.4)
Other 3 (4.2)
Table 6. Indications for methadone use
n (%)
Neuropathic pain 23 (14.6)
Severe renal impairment 9 (5.7)
Other 6 (3.8)
High opioid tolerance 2 (1.3)
Morphine allergy 3 (1.9)
Refractory to other opioids 2 (1.2)
Conclusion 
▪ Ongoing analysis will continue to assess the data collected to identify patterns in recommendations 
that were provided versus those that were not. 
▪ Further analysis will provide an opportunity to explore methadone interactions with comorbidities as 
a reason for limited acceptance among physicians
Table 2. Type of pain 
n (%)
Nociceptive 62 (39.2)
Neuropathic  5 (3.2)
Both 4 (21.5)
Missing 57 (36.0)
Table 4. Type of pain medication
n (%)
Opioids 153 (96.8)
APAP 55 (34.8)
Opioid/APAP 19 (12.0)
NSAID 6 (3.7)
Gabapentinoids 16 (10.1)
Other 12 (7.6)
Table 3. Hospice type
n (%)
Home 121 (76.6)
Nursing home 22 (13.9)
Assisted living 10 (6.3)
Inpatient 4 (2.5)
Missing 1 (0.6)
Note: One patient can be included in more than one category
Note: One patient can be included in more than one category
